Results 61 to 70 of about 101,340 (329)

Harnessing Photo‐Energy Conversion in Nanomaterials for Precision Theranostics

open access: yesAdvanced Materials, EarlyView.
Harnessing photo‐energy conversion in nanomaterials enables precision theranostics through light‐driven mechanisms such as photoluminescence, photothermal, photoelectric, photoacoustic, photo‐triggered surface‐enhanced Raman scattering (SERS), and photodynamic processes. This review explores six fundamental principles of photo‐energy conversion, recent
Jingyu Shi   +4 more
wiley   +1 more source

Dopamine-independent locomotor actions of amphetamines in a novel acute mouse model of Parkinson disease. [PDF]

open access: yesPLoS Biology, 2005
Brain dopamine is critically involved in movement control, and its deficiency is the primary cause of motor symptoms in Parkinson disease. Here we report development of an animal model of acute severe dopamine deficiency by using mice lacking the ...
Tatyana D Sotnikova   +5 more
doaj   +2 more sources

Rewiring Neuroimmunity: Nanoplatform Innovations for CNS Disease Therapy

open access: yesAdvanced Therapeutics, EarlyView.
This review explores emerging nanoplatform strategies designed to modulate neuroimmune responses for treating central nervous system (CNS) disorders. It examines structural and microenvironmental barriers, advances in multifunctional and targeted nanotechnologies, and highlights clinical progress and translational challenges, offering insights into the
Muhammad Usman Akbar   +7 more
wiley   +1 more source

D₂ Dopamine Receptors Colocalize Regulator of G-Protein Signaling 9-2 (RGS9-2) via the RGS9 DEP Domain, and RGS9 Knock-Out Mice Develop Dyskinesias Associated with Dopamine Pathways [PDF]

open access: yes, 2005
Regulator of G-protein signaling 9-2 (RGS9-2), a member of the RGS family of Gα GTPase accelerating proteins, is expressed specifically in the striatum, which participates in antipsychotic-induced tardive dyskinesia and in levodopa-induced dyskinesia. We
Axelrod, Jeffrey D.   +10 more
core  

Cognitive impairment induced by delta9-tetrahydrocannabinol occurs through heteromers between cannabinoid CB1 and serotonin 5-HT2A receptors [PDF]

open access: yes, 2015
Delta-9-tetrahydrocannabinol (THC), the main psychoactive compound of marijuana, induces numerous undesirable effects, including memory impairments, anxiety, and dependence.
A Busquets-Garcia   +112 more
core   +5 more sources

Dopamine agonists and Othello’s syndrome [PDF]

open access: yesParkinsonism & Related Disorders, 2010
Othello's syndrome (OS) is a delusion of infidelity. We describe seven cases of OS in Parkinson's disease (iPD) patients using dopamine agonists.We searched the Mayo Clinic Medical Records System to identify all patients with OS. Clinical data abstracted include sex, age of onset of iPD, age of onset of OS, medications, effect of discontinuing the ...
James H. Bower   +3 more
openaire   +3 more sources

Inhibition of Phosphodiesterase 10A by MP‐10 Rescues Behavioral Deficits and Normalizes Microglial Morphology and Synaptic Pruning in A Mouse Model of FOXP1 Syndrome

open access: yesAdvanced Science, EarlyView.
We demonstrate that Foxp1± mice, modeling FOXP1 haploinsufficiency, exhibit behavioral deficits, striatal neuroinflammatory changes including altered microglial complexity and synaptic pruning, and markedly reduced Pde10a expression. Pde10a inhibition starting immediately after birth restores Foxp1± behavior, microglial morphology, and pruning ...
Henning Fröhlich   +8 more
wiley   +1 more source

Dopamine-induced apoptosis of lactotropes is mediated by the short isoform of D2 receptor. [PDF]

open access: yesPLoS ONE, 2011
Dopamine, through D2 receptor (D2R), is the major regulator of lactotrope function in the anterior pituitary gland. Both D2R isoforms, long (D2L) and short (D2S), are expressed in lactotropes.
Daniela Betiana Radl   +5 more
doaj   +1 more source

Rasagiline Withdrawal Syndrome in Parkinson’s Disease

open access: yesBrain Sciences, 2022
Parkinson’s disease (PD) patients using dopamine agonists can develop withdrawal symptoms, referred to as dopamine agonist withdrawal syndrome (DAWS), under dose tapering or discontinuation of these drugs.
Paolo Solla   +10 more
doaj   +1 more source

Serotonin, Motivation, and Playfulness in the Juvenile Rat [PDF]

open access: yes, 2011
The effects of the selective 5HT1A agonist 8-OH-DPAT were assessed on the play behavior of juvenile rats. When both rats of the test pair were comparably motivated to play, the only significant effect of 8-OH-DPAT was for play to be reduced at higher ...
Deron, Loren M.   +2 more
core   +2 more sources

Home - About - Disclaimer - Privacy